DyoDelta Biosciences Ltd.’s Post

Pharma-biotech deals continue at a fast pace, demonstrating the interdependence of small and large companies in the sector. In a strategic move indicative of the pharmaceutical industry’s continued pursuit of innovative therapies, GlaxoSmithKline (GSK) has recently sealed a substantial deal in the antibody-drug conjugate (ADC) space. GSK announced an agreement with China-based Hansoh Pharma, marking a significant investment of approximately $1.7 billion. Under the terms of this expansive deal, GSK secures an exclusive license agreement for the global rights to Hansoh’s B7-H3 targeted antibody-drug conjugate (ADC), known as HS-20093. The agreement involves an initial payment of $185 million upfront. While Hansoh retains rights to the drug within mainland China, Taiwan, Macau, and Hong Kong, GSK assumes responsibility for the clinical development and subsequent commercialization of this promising ADC. The financial dynamics of the deal encompass potential tiered royalties from the global sales of HS-20093 to be paid by GSK to Hansoh. Additionally, Hansoh stands to receive milestone payments amounting to a staggering $1.525 billion based on the drug’s development progress and commercial achievements. Commenting on the significance of this agreement, Hesham Abdullah, Senior Vice President and Global Head of Oncology at GSK, highlighted the potential impact of B7-H3 in treating a broad spectrum of solid tumors. The expression of B7-H3 in various tumors underscores the critical need for innovative therapeutic interventions. Abdullah expressed anticipation for advancing this potential treatment across multiple indications and exploring future combination approaches within GSK’s established portfolio. As part of GSK’s strategic portfolio, HS-20093 represents the second ADC in the clinical stage for the UK-based pharmaceutical giant. Presently undergoing Phase I and Phase II trials in China, HS-20093 has demonstrated promising early clinical activity in patients with small cell lung cancer, non-small cell lung cancer, and sarcoma. GSK plans to extend the clinical evaluation of HS-20093 beyond China, commencing Phase I trials in 2024. In the broader context of pharmaceutical industry trends, such substantial investments underscore the strategic importance placed on biotech partnerships, demonstrating the industry’s keen interest in acquiring or licensing novel drugs. GSK’s commitment to advancing ADC therapies exemplifies the company’s dedication to innovation, therapeutic diversity, and addressing unmet medical needs. As the pharmaceutical landscape continues to evolve, such strategic alliances are expected to play a pivotal role in shaping the future of drug development and patient care. #pharma #pharmaceuticals #biotechnology #deals #collaborations #alliances #acquisitions #gsk

Sanofi in $140m Artificial Intelligence Drug Discovery Deal In a significant move for the pharmaceutical industry, Sanofi and AI specialist Aqemia have entered a substantial multi-year research collaboration. The $140 million deal aims to discover small molecule drug candidates across various therapeutic areas. This collaboration uniquely combines Sanofi's robust research and development capabilities with Aqemia's platform, integrating deep physics and generative AI on a large scale to identify novel drug molecules for therapeutic targets. Aqemia's approach, distinct from conventional AI-based platforms, generates its data from the earliest stages of drug discovery using unique quantum physics algorithms. The partnership covers the entire drug discovery process, from identifying the initial 'hits' to selecting the development candidate. Sanofi will be responsible for wet lab research, development, and commercialization, with Aqemia potentially receiving up to $140 million in upfront and milestone payments across all programs. This collaboration builds upon the companies' existing oncology-focused partnership initiated in 2020 and extended in 2022. Jacques Volckmann, Sanofi’s Vice President of Research and Development for France, highlighted the ongoing story that began three years ago and praised Aqemia's technology development. Maximilien Levesque, CEO and Co-founder of Aqemia, emphasized scaling expertise for multiple projects and supporting Sanofi in discovering novel chemical matter at scale. The announcement follows Sanofi's recent partnership with BioMap, showcasing the company's commitment to AI-driven collaborations. In this evolving landscape of pharmaceutical innovation, strategic collaborations and effective deal-making are paramount. DyoDelta stands ready to assist, leveraging expertise in facilitating deals, raising capital, and navigating collaborations. Explore new frontiers with DyoDelta Biosciences. #sanofi #pharmaceuticals #pharma #biotech #deals #pharmainnovation #collaboration #alliance #ai #digitalhealth https://lnkd.in/d2axbjRR?

Exciting News in Biotech! EyeBio Secures $130M in Extended Series A Funding! Thrilled to share that EyeBio has successfully closed an extension to its Series A financing, raising a remarkable $130 million! This funding round welcomes new heavyweights like Bain Capital Life Sciences, Omega Funds, and Vertex Ventures HC, joining existing investors. This significant achievement allows EyeBio to accelerate clinical development, with a special focus on advancing the AMARONE clinical trial and the groundbreaking Restoret. As the CEO, David Guyer, rightly puts it, “The expansion of our Series A round in the current fundraising environment speaks to our investors’ enthusiasm for what the EyeBio team is accomplishing.” Notable Quotes from industry leaders: “We look forward to partnering with David Guyer and the world-class team at EyeBio to contribute to building a great company together.” – Bernard Davitian, Partner at Omega Funds “EyeBio’s potential breakthrough solution presents tremendous potential in enhancing patient care and treatment outcomes for millions affected by sight-threatening disease.” – Christine Brennan, PhD, Managing Director at Vertex Ventures HC The success of this funding round underscores the importance of how an opportunity is presented in the biotech industry. EyeBio’s clear communication and strategic approach played a crucial role in attracting heavyweight investors. Crafting a compelling story is key, and this is an area where DyoDelta excels—helping companies present their opportunities effectively, whether in funding rounds or strategic partnerships. Congratulations to EyeBio’s seasoned executive team! This funding is a strategic bet on their capacity to revolutionize patient care in ophthalmology. As the industry watches, the success of the AMARONE trial and the progression of Restoret will be critical indicators of EyeBio’s transformative impact on retinal disease treatment. #biotech #fundraising #raisingcapital #investing #investors #investorrelations #capital #capitalraising #pharma #pharmaceutical #therapeutics #series https://lnkd.in/gYf9cayE

Unraveling the 3D Genome Organization - Insights from CNRS's Research Ever wondered how the genome, far from being a linear sequence of genes, is intricately organized within the three-dimensional space of the cell nucleus? The researchers at CNRS (French National Centre for Scientific Research) have delved deep into this captivating world, shedding light on the fascinating DNA structures. Within the nucleus, genes are not just isolated entities, but instead, they dance in harmony within chromosomal domains. These domains, characterized by varying types of active and repressive chromatin, create an elaborate tapestry of interactions. In this groundbreaking research, CNRS scientists have uncovered a pivotal concept: domains within a chromosome form specific connections, giving rise to topologically associated domains (TADs). These TADs interact preferentially with others of the same type, forming structured 3D chromosomal territories. The DNA symphony doesn't stop there. CNRS's work emphasizes the vital roles of Polycomb (PcG) and Trithorax (trxG) proteins, the maestros of gene regulation. PcG proteins maintain the memory of silent gene expression states across cell divisions, while trxG proteins sustain active chromatin states. Remarkably, these chromatin states can influence the destiny of successive generations, showcasing the intricate interplay between genetics and inheritance. CNRS's research not only deciphers 3D genome organization principles but also explores the functional implications and complex molecular mechanisms orchestrating gene expression and development. Armed with a diverse toolkit spanning molecular biology, genomics, and bioinformatics, CNRS researchers continue to decode the enigmatic dance of DNA. https://lnkd.in/dNaafKcJ #GenomicResearch #DNAStructure #CNRSInsights #ScientificDiscovery #cnrs #dna